Characteristics and outcome of the 541 patients according to karyotype
| . | Karyotype available . | . | . | ||
|---|---|---|---|---|---|
| . | MNC 51-53 (n = 87) . | MNC 54-57 (n = 258) . | MNC 58-66 (n = 101) . | Karyotype not available (n = 95) . | Total (n = 541) . |
| Gender, n (%) | |||||
| Male | 42 (48.3) | 128 (49.6) | 63 (62.4) | 59 (62.1) | 292 (54.0) |
| Female | 45 (51.7) | 130 (50.4) | 38 (37.6) | 36 (37.9) | 249 (46.0) |
| Age | |||||
| Median, years (range) | 3 (0-17) | 4 (1-17) | 3 (1-16) | 3 (1-17) | 3 (0-17) |
| <1 , n (%) | 1 (1.1) | 0 (0) | 0 (0) | 0 (0) | 1 (0.2) |
| 1-2 , n (%) | 5 (5.7) | 27 (10.5) | 9 (8.9) | 12 (12.6) | 53 (9.8) |
| 2-5 , n (%) | 58 (66.7) | 151 (58.5) | 70 (69.3) | 58 (61.1) | 337 (62.3) |
| 6-9 , n (%) | 12 (13.8) | 45 (17.4) | 11 (10.9) | 15 (15.8) | 83 (15.3) |
| ≥10 , n (%) | 11 (12.6) | 35 (13.6) | 11 (10.9) | 10 (10.5) | 67 (12.4) |
| WBC | |||||
| Median, ×109 per liter (range) | 6.9 (1-164) | 5.4 (0.4-160) | 5.4 (0.8-100.3) | 4.7 (0.3-176.4) | 5.6 (0.3-176.4) |
| <10 × 109 per liter, n (%) | 54 (62.1) | 185 (71.7) | 70 (69.3) | 73 (76.8) | 382 (70.6) |
| 10 to <25 × 109 per liter, n (%) | 15 (17.2) | 34 (13.2) | 19 (18.8) | 14 (14.7) | 82 (15.2) |
| 25 to <100 × 109 per liter, n (%) | 17 (19.5) | 35 (13.6) | 11 (10.9) | 5 (5.3) | 68 (12.6) |
| ≥100 × 109 per liter, n (%) | 1 (1.1) | 4 (1.6) | 1 (1.0) | 3 (3.2) | 9 (1.7) |
| PB blast count | |||||
| Median, × 109/L (range) | 2.3 (0-139) | 1.3 (0-141) | 0.8 (0-92) | 0.7 (0-146) | 1.2 (0-146) |
| BM blasts | |||||
| Median, % (range) | 95 (41-99) | 94 (32-99) | 92 (27-99) | 90 (14-99) | 94 (14-99) |
| NCI risk groups, n (%) | |||||
| SR | 70 (80.5) | 203 (78.7) | 85 (84.2) | 82 (86.3) | 440 (81.3) |
| HR | 17 (19.5) | 55 (21.3) | 16 (15.8) | 13 (13.7) | 101 (18.7) |
| Trisomy/tetrasomy, n (%) | |||||
| Chromosome 4 | 46 [54]‡ | 195 [78]‡ | 87 [92]‡ | 27 [90]† | 355 [77]‡ |
| Chromosome 10 | 31 [37]‡ | 172 [69]‡ | 79 [83]‡ | 25 [81]† | 307 [67]‡ |
| Chromosome 17 | 38 [46]‡ | 170 [69]‡ | 70 [77]‡ | 23 [96]† | 301 [68]‡ |
| Chromosome 18 | 39 [48]‡ | 201 [81]‡ | 71 [79]‡ | 17 [85]† | 328 [75]‡ |
| Trisomies 4, 10 | 17 [20]‡ | 131 [52]‡ | 73 [76]‡ | 21 [64] † | 242 [52]‡ |
| Trisomies 4, 10, 17 | 6 [7]‡ | 94 [37]‡ | 54 [56]‡ | 14 [41]† | 168 [36]‡ |
| Trisomies 4, 10, 18 | 5 [6]‡ | 108 [43]‡ | 56 [58]‡ | 11 [32]† | 180 [38]‡ |
| Measured DNA index, n (%) | |||||
| <1.16 | 63 (72.4) | 58 (22.5) | 4 (4.0) | 21 (22.1) | 146 (27.0) |
| ≥1.16 to <1.24 | 14 (16.1) | 156 (60.5) | 18 (17.8) | 52 (54.7) | 240 (44.4) |
| ≥1.24 | 2 (2.3) | 17 (6.6) | 66 (65.3) | 19 (20.0) | 104 (19.2) |
| Not assessed | 8 (9.2) | 27 (10.5) | 13 (12.9) | 3 (3.2) | 51 (9.4) |
| Prephase response, n (%) | |||||
| Good | 85 (98) | 249 (96.5) | 101 (100) | 89 (93.7) | 524 (96.9) |
| Poor | 2 (2) | 9 (3.5) | 0 (0) | 6 (6.3) | 17 (3.1) |
| EORTC risk groups, n (%) | |||||
| VLR | 17 (19.5) | 124 (48.1) | 56 (55.4) | 30 (31.6) | 227 (42) |
| AR low | 65 (74.7) | 111 (43.0) | 42 (41.6) | 56 (58.9) | 274 (50.6) |
| AR high | 3 (3.4) | 14 (5.4) | 3 (3.0) | 3 (3.2) | 23 (4.3) |
| VHR | 2 (2.3) | 9 (3.5) | 0 (0) | 6 (6.3) | 17 (3.1) |
| Complete remission, n (%) | 87 (100) | 257 (99.6) | 101 (100) | 95 (100) | 540 (99.8) |
| MRD at D35, n (%) | |||||
| <10−3 | 65 [83]§ | 204 [92.7]§ | 81 [96.4]§ | 69 [94.5]§ | 419 [91.5]§ |
| ≥10−3 to <10−2 | 9 [11.5]§ | 12 [5.4]§ | 2 [2.4]§ | 3 [4.1]§ | 26 [5.7]§ |
| ≥10−2 | 4 [5.1]§* | 7 [3.2]§* | 1 [1.2]§* | 1 [1.4]§* | 13 [2.8]§ |
| Not assessed | 9 | 38 | 17 | 22 | 83 |
| EFS status, n (%) | |||||
| No CR (induction death) | 0 (0) | 1 (0.4) | 0 (0) | 0 (0) | 1 (0.2) |
| CCR | 70 (80.5) | 232 (90.0) | 100 (99.0) | 84 (88.4) | 486 (89.8) |
| Relapse | 15 (17.2) | 21 (8.1) | 1 (1.0) | 11 (11.6) | 48 (8.9) |
| BM only | 10 | 12 | 1 | 8 | 31 |
| CNS only | 1 | 4 | 0 | 0 | 5 |
| CNS combined | 2 | 1 | 0 | 2 | 5 |
| Other | 2 | 4 | 0 | 1 | 7 |
| TRM | 2 (2.3) | 4 (1.6) | 0 (0) | 0 (0) | 6 (1.1) |
| Survival, n (%) | |||||
| Alive | 78 (89.7) | 249 (96.5) | 101 (100) | 91 (95.8) | 519 (95.9) |
| Dead | 9 (10.3) | 9 (3.5) | 0 (0) | 4 (4.2) | 22 (4.1) |
| . | Karyotype available . | . | . | ||
|---|---|---|---|---|---|
| . | MNC 51-53 (n = 87) . | MNC 54-57 (n = 258) . | MNC 58-66 (n = 101) . | Karyotype not available (n = 95) . | Total (n = 541) . |
| Gender, n (%) | |||||
| Male | 42 (48.3) | 128 (49.6) | 63 (62.4) | 59 (62.1) | 292 (54.0) |
| Female | 45 (51.7) | 130 (50.4) | 38 (37.6) | 36 (37.9) | 249 (46.0) |
| Age | |||||
| Median, years (range) | 3 (0-17) | 4 (1-17) | 3 (1-16) | 3 (1-17) | 3 (0-17) |
| <1 , n (%) | 1 (1.1) | 0 (0) | 0 (0) | 0 (0) | 1 (0.2) |
| 1-2 , n (%) | 5 (5.7) | 27 (10.5) | 9 (8.9) | 12 (12.6) | 53 (9.8) |
| 2-5 , n (%) | 58 (66.7) | 151 (58.5) | 70 (69.3) | 58 (61.1) | 337 (62.3) |
| 6-9 , n (%) | 12 (13.8) | 45 (17.4) | 11 (10.9) | 15 (15.8) | 83 (15.3) |
| ≥10 , n (%) | 11 (12.6) | 35 (13.6) | 11 (10.9) | 10 (10.5) | 67 (12.4) |
| WBC | |||||
| Median, ×109 per liter (range) | 6.9 (1-164) | 5.4 (0.4-160) | 5.4 (0.8-100.3) | 4.7 (0.3-176.4) | 5.6 (0.3-176.4) |
| <10 × 109 per liter, n (%) | 54 (62.1) | 185 (71.7) | 70 (69.3) | 73 (76.8) | 382 (70.6) |
| 10 to <25 × 109 per liter, n (%) | 15 (17.2) | 34 (13.2) | 19 (18.8) | 14 (14.7) | 82 (15.2) |
| 25 to <100 × 109 per liter, n (%) | 17 (19.5) | 35 (13.6) | 11 (10.9) | 5 (5.3) | 68 (12.6) |
| ≥100 × 109 per liter, n (%) | 1 (1.1) | 4 (1.6) | 1 (1.0) | 3 (3.2) | 9 (1.7) |
| PB blast count | |||||
| Median, × 109/L (range) | 2.3 (0-139) | 1.3 (0-141) | 0.8 (0-92) | 0.7 (0-146) | 1.2 (0-146) |
| BM blasts | |||||
| Median, % (range) | 95 (41-99) | 94 (32-99) | 92 (27-99) | 90 (14-99) | 94 (14-99) |
| NCI risk groups, n (%) | |||||
| SR | 70 (80.5) | 203 (78.7) | 85 (84.2) | 82 (86.3) | 440 (81.3) |
| HR | 17 (19.5) | 55 (21.3) | 16 (15.8) | 13 (13.7) | 101 (18.7) |
| Trisomy/tetrasomy, n (%) | |||||
| Chromosome 4 | 46 [54]‡ | 195 [78]‡ | 87 [92]‡ | 27 [90]† | 355 [77]‡ |
| Chromosome 10 | 31 [37]‡ | 172 [69]‡ | 79 [83]‡ | 25 [81]† | 307 [67]‡ |
| Chromosome 17 | 38 [46]‡ | 170 [69]‡ | 70 [77]‡ | 23 [96]† | 301 [68]‡ |
| Chromosome 18 | 39 [48]‡ | 201 [81]‡ | 71 [79]‡ | 17 [85]† | 328 [75]‡ |
| Trisomies 4, 10 | 17 [20]‡ | 131 [52]‡ | 73 [76]‡ | 21 [64] † | 242 [52]‡ |
| Trisomies 4, 10, 17 | 6 [7]‡ | 94 [37]‡ | 54 [56]‡ | 14 [41]† | 168 [36]‡ |
| Trisomies 4, 10, 18 | 5 [6]‡ | 108 [43]‡ | 56 [58]‡ | 11 [32]† | 180 [38]‡ |
| Measured DNA index, n (%) | |||||
| <1.16 | 63 (72.4) | 58 (22.5) | 4 (4.0) | 21 (22.1) | 146 (27.0) |
| ≥1.16 to <1.24 | 14 (16.1) | 156 (60.5) | 18 (17.8) | 52 (54.7) | 240 (44.4) |
| ≥1.24 | 2 (2.3) | 17 (6.6) | 66 (65.3) | 19 (20.0) | 104 (19.2) |
| Not assessed | 8 (9.2) | 27 (10.5) | 13 (12.9) | 3 (3.2) | 51 (9.4) |
| Prephase response, n (%) | |||||
| Good | 85 (98) | 249 (96.5) | 101 (100) | 89 (93.7) | 524 (96.9) |
| Poor | 2 (2) | 9 (3.5) | 0 (0) | 6 (6.3) | 17 (3.1) |
| EORTC risk groups, n (%) | |||||
| VLR | 17 (19.5) | 124 (48.1) | 56 (55.4) | 30 (31.6) | 227 (42) |
| AR low | 65 (74.7) | 111 (43.0) | 42 (41.6) | 56 (58.9) | 274 (50.6) |
| AR high | 3 (3.4) | 14 (5.4) | 3 (3.0) | 3 (3.2) | 23 (4.3) |
| VHR | 2 (2.3) | 9 (3.5) | 0 (0) | 6 (6.3) | 17 (3.1) |
| Complete remission, n (%) | 87 (100) | 257 (99.6) | 101 (100) | 95 (100) | 540 (99.8) |
| MRD at D35, n (%) | |||||
| <10−3 | 65 [83]§ | 204 [92.7]§ | 81 [96.4]§ | 69 [94.5]§ | 419 [91.5]§ |
| ≥10−3 to <10−2 | 9 [11.5]§ | 12 [5.4]§ | 2 [2.4]§ | 3 [4.1]§ | 26 [5.7]§ |
| ≥10−2 | 4 [5.1]§* | 7 [3.2]§* | 1 [1.2]§* | 1 [1.4]§* | 13 [2.8]§ |
| Not assessed | 9 | 38 | 17 | 22 | 83 |
| EFS status, n (%) | |||||
| No CR (induction death) | 0 (0) | 1 (0.4) | 0 (0) | 0 (0) | 1 (0.2) |
| CCR | 70 (80.5) | 232 (90.0) | 100 (99.0) | 84 (88.4) | 486 (89.8) |
| Relapse | 15 (17.2) | 21 (8.1) | 1 (1.0) | 11 (11.6) | 48 (8.9) |
| BM only | 10 | 12 | 1 | 8 | 31 |
| CNS only | 1 | 4 | 0 | 0 | 5 |
| CNS combined | 2 | 1 | 0 | 2 | 5 |
| Other | 2 | 4 | 0 | 1 | 7 |
| TRM | 2 (2.3) | 4 (1.6) | 0 (0) | 0 (0) | 6 (1.1) |
| Survival, n (%) | |||||
| Alive | 78 (89.7) | 249 (96.5) | 101 (100) | 91 (95.8) | 519 (95.9) |
| Dead | 9 (10.3) | 9 (3.5) | 0 (0) | 4 (4.2) | 22 (4.1) |
TRM, treatment-related mortality.
Percentages calculated on cases assessed by FISH.
Percentages calculated on cases with gains assessable (either on karyotype or on FISH or both).
Data obtained from patients with MRD assessable.
Patients switched to VHR: 3 in the 51-53 group, 5 in the 54-57 group, 1 in the 58-66 group, and 1 in the karyotype not available group.